Benefit assessment in Germany : implications for price discounts
Year of publication: |
Dezember 2016
|
---|---|
Authors: | Theidel, Ulrike ; Schulenburg, Johann-Matthias von der |
Published in: |
Health economics review. - Heidelberg : Springer, ISSN 2191-1991, ZDB-ID 2634483-X. - Vol. 6.2016, 33, p. 1-12
|
Subject: | Health policy | Pharmaceuticals | Market access | Rebate | Negotiation | New substance | Deutschland | Germany | Arzneimittel | Gesundheitspolitik | Rabatt | Pharmaindustrie | Pharmaceutical industry | Markteintritt | Market entry |
Type of publication: | Article |
---|---|
Type of publication (narrower categories): | Aufsatz in Zeitschrift ; Article in journal |
Language: | English |
Other identifiers: | 10.1186/s13561-016-0109-3 [DOI] hdl:10419/175600 [Handle] |
Source: | ECONIS - Online Catalogue of the ZBW |
-
Medikamenten Monopoly : die unheilvolle Welt der Arzneimittelgeschäfte
Stadler, Franz, (2020)
-
Parallel imports and manufacturer rebates : evidence from Germany
Birg, Laura, (2019)
-
Parallel imports under a manufacturer rebate and a price freeze : evidence from Germany
Birg, Laura, (2023)
- More ...
-
Theidel, Ulrike, (2017)
-
Benefit assessment in Germany: Implications for price discounts
Theidel, Ulrike, (2016)
-
Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
Kuhlmann, Alexander, (2012)
- More ...